Which medications in the drug class Complete Regimen Combinations are used in the treatment of Pediatric HIV Infection?

Updated: Mar 05, 2020
  • Author: Delia M Rivera, MD; Chief Editor: Russell W Steele, MD  more...
  • Print
Answer

Complete Regimen Combinations

Complete fixed-dose regimens assist with medication adherence. Three- and four-drug combination products are available to decrease pill burden and administration frequency.

Emtricitabine/tenofovir/efavirenz (Atripla)

Contains emtricitabine and tenofovir (NRTIs), plus efavirenz (NNRTI). Indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients aged ≥ 12 years who weigh at least 40 kg.

Elvitegravir/cobicistat/emtricitabine/tenofovir AF (Genvoya)

Four-drug antiretroviral (ART) combination of elvitegravir (integrase strand transfer inhibitor [INSTI]), cobicistat (CYP3A inhibitor), and emtricitabine and tenofovir alafenamide (TAF), both nucleoside analog reverse transcriptase inhibitors (NRTIs). It is indicated as a complete treatment regimen for HIV-1 infection in adults and children aged ≥ 12 y (weight ≥ 25 kg) who are ART-naïve or to replace the current ART regimen in those who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable ART regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components.

Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Stribild)

Combination integrase inhibitor, CYP3A4 inhibitor (boosted therapy), and 2 NRTIs as a complete regimen for treatment of HIV infection in treatment-naive pediatric patients aged ≥ 12 y who weigh at least 35 kg. It is also indicated as replacement of the current antiretroviral regimen in patients who are virologically-suppressed (HIV-1 RNA < 50 copies/mL) on a stable ART regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Stribild.

Emtricitabine/rilpivirine/tenofovir DF (Complera)

Indicated as complete regimen for treatment of HIV-1 infection in treatment-naïve adults and adolescents aged 12 years or older (weight ≥ 35 kg) with HIV-1 RNA > 100,000 copies/mL, and in certain virologically-suppressed (HIV-1 RNA < 50 copies/mL) patients on a stable ART regimen at start of therapy in order to replace their current ART regimen. Combination consists of 2 NRTIs (ie, emtricitabine and tenofovir) and 1 NNRTI (ie, rilpivirine).

Emtricitabine/rilpivirine/tenofovir AF (Odefsey)

Indicated as complete regimen for treatment of HIV-1 infection in treatment-naïve adults and adolescents aged 12 years or older (weight ≥ 35 kg) with HIV-1 RNA > 100,000 copies/mL, and in certain virologically-suppressed (HIV-1 RNA < 50 copies/mL) patients on a stable ART regimen at start of therapy in order to replace their current ART regimen. Combination consists of 2 NRTIs (ie, emtricitabine and tenofovir) and 1 NNRTI (ie, rilpivirine).

Efavirenz/lamivudine/tenofovir DF (Symfi, Symfi Lo)

Three-drug combination of a non-nucleoside reverse transcriptase inhibitor, and two nucleo(t)side reverse transcriptase inhibitors and is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and children who weigh at least 35 kg (Symfi Lo) or 40 kg (Symfi).

Bictegravir/emtricitabine/tenofovir AF (Biktarvy)

Three-drug combination of bictegravir (BIC), an HIV-1 integrase strand transfer inhibitor (INSTI), and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors (NRTIs). Indicated as a complete regimen for treatment of HIV-1 infection in adults and pediatric patients weighing ≥25 kg who are ART-naïve or replacing current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA

Darunavir/cobicistat/emtricitabine/tenofovir AF (Symtuza)

Four-drug combination of darunavir (DRV), a protease inhibitor, cobicistat, and FTC and TAF is indicated for HIV-1 infection in adults and adolescents weighing at least 40 kg who have no prior antiretroviral (ART) treatment history or who are virologically suppressed (HIV-1 RNA


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!